Ensayos clínicos Solicite una Consulta en Mayo Clinic Centros, viajes y alojamientoInvestigación March 21, 2020 Comparte en: FacebookTwitter A continuación se enumeran ensayos clínicos actuales.613 estudios en Oncología (médica) (estudios abiertos únicamente). Filtrar esta lista de estudios según la ubicación, el estado del estudio y más. A Study to Evaluate Circulating Cell Free Tumor DNA as a Biomarker in Sarcoma Rochester, Minn. The purpose of this study is to determine the feasibility of ctDNA detection in patients with advanced translocation-associated sarcomas. A Study to Evaluate the Venn Ovarian CAncer Liquid Biopsy Jacksonville, Fla. The primary purpode of this study is to determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the InterVenn Ovarian Cancer Liquid Biopsy among women with ovarian adnexal mass for which a surgery is planned. P1101 in Treating Patients With Early Myelofibrosis Scottsdale/Phoenix, Ariz. This pilot phase II trial studies P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with early myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of early myelofibrosis. Cutaneous Lymphoma Database Scottsdale/Phoenix, Ariz. The purpose of this study is to create a long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions. Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Rochester, Minn., Scottsdale/Phoenix, Ariz. This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Scottsdale/Phoenix, Ariz. This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®). Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Scottsdale/Phoenix, Ariz. This study is designed to study the effect of an investigational drug, IPI-549, when given in combination with nivolumab (OPDIVO®) as compared with nivolumab alone. IPI-549 is designed to stop cancer growth by blocking PI3-kinase activity. When PI3-kinase (an enzyme that is a part of immune cells) is blocked, some immune cells may become activated and slow down tumor growth or possibly prevent it from growing. Nivolumab has been approved by the FDA to treat patients with various cancers including cancer of the urinary system (urothelial carcinoma). A Study to Determine the Effects of Activity by Ambulation in Hospital Premises versus Strict Protective Isolation on Quality of Life in Severely Neutropenic Cancer Patients during Hospitalization Jacksonville, Fla. The purpose of this study is to determine if allowing patients to ambulate in the hallways outside of their hospital room by relaxing the policy of strict protective isolation in neutropenic patients improves the quality of life, and if this increases the risk of infection among these patients during hospitalization. Study Using Chromogranin A as Surveillance Biomarker in Patients with cARcinoids Rochester, Minn. The purpose of this study is to monitor and validate the performance and stability of the BRAHMS Chromogranin A (CgA) II KRYPTOR Assay in patients with Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs). A Study to Determine the Best Individualized Cancer Therapy Using Circulating Tumor DNA (ctDNA) in Patients with GI, CNS, and Thoracic Cancers. Jacksonville, Fla. This study proposes to develop and maintain a biorepository of blood samples collected from patients receiving definitive chemoradiotherapy for locally advanced rectal cancer, locally advanced pancreatic cancer, non-small cell lung cancer, or cervical cancer. The ultimate goal of this biorepository will be to provide the resource to initiate an exploration of ctDNA as a potential liquid biopsy for GI and Thoracic malignancy detection and surveillance. Numeración de páginas Estudios clínicos Ir a página 11 Ir a página 22 Ir a página 33 Ir a página 44 Ir a página 55 SiguientePróxima página Mayo Clinic en Rochester, Minnesota, Mayo Clinic en Phoenix/Scottsdale, Arizona, y Mayo Clinic en Jacksonville, Florida, han sido reconocidas como unos de los mejores hospitales de cáncer del país durante el período 2020-2021 por la revista U.S. News and World Report. Lee más sobre este gran honor. Oncología (médica)Página inicial del departamentoSeccionesSolicita una consultaDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRecursos para profesionales en Medicina Investigación: todo es por los pacientes SeccionesSolicita una consultaDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRecursos para profesionales en Medicina ORG-20180179 Departamentos y centros Departamentos y centros médicos Oncología (médica)